BioCryst Pharmaceuticals BCRX Current State And Local Tax Expense Benefit
Current State And Local Tax Expense Benefit at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CurrentStateAndLocalTaxExpenseBenefit.
The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's current state and local tax expense benefit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's current state and local tax expense benefit?
- BioCryst Pharmaceuticals (BCRX) reported current state and local tax expense benefit of $875.5K in Q4 2025.
- How has BioCryst Pharmaceuticals's current state and local tax expense benefit changed year-over-year?
- BioCryst Pharmaceuticals's current state and local tax expense benefit increased by 213.2% year-over-year, from $279.5K to $875.5K.
- What is the long-term trend for BioCryst Pharmaceuticals's current state and local tax expense benefit?
- Over 2 years (2023 to 2025), BioCryst Pharmaceuticals's current state and local tax expense benefit has grown at a 782.2% compound annual growth rate (CAGR), from -$45K to $3.5M.
- What does current state and local tax expense benefit mean?
- The current income tax expense or benefit payable to state and local jurisdictions based on the company's operations in those specific regions. This metric captures the regional tax obligations that supplement federal taxes. It is useful for evaluating the impact of geographic operational distribution on the overall tax profile.